Autologous Tumor Infiltrating Lymphocyte (TIL) Platform
From Research Services & Partnering - Translational Research - Immuno-Oncology Platforms
Champions Oncology's ex vivo 3D co-culture platform for Immuno-Oncology therapeutic testing. Champions Oncology has launched an innovative new platform enabling Immuno-Oncology researchers the ability to test their therapeutics in a 3D organoid assay that can mimic mechanism of action. The Autologous TIL platform is an ex vivo 3D co-culture platform developed and optimized to interrogate the responses of your Immuno-Oncology drugs with a tumor-specific microenvironment in only 4 days using PDX-O (patient-derived xenograft organoids) collected with matched, autologous TIL samples.
Autologous TIL Platform Methodology
The scientific endpoints of this platform are: ima...
The scientific endpoints of this platform are: imaging using confocal microscopy, HCA assay with tumor cytotoxicity and TIL infiltration readouts, flow cytometry assessment of TIL cellular constituents and supernatant cytokine assessment by Luminex.
Confocal High Content Analysis Assay
Customer reviews
No reviews were found for Autologous Tumor Infiltrating Lymphocyte (TIL) Platform. Be the first to review!